Atossa Therapeutics Inc

NASDAQ:ATOS   3:59:42 PM EDT
1.60
+0.03 (+1.91%)
Products

Atossa Therapeutics Announces Preliminary Results From Phase 1 Clinical Study Showing Safety And Tolerability Of AT-301 Nasal Spray Being Developed For Covid-19

Published: 11/10/2020 14:43 GMT
Atossa Genetics Inc (ATOS) - Atossa Therapeutics Announces Preliminary Results From Phase 1 Clinical Study Showing Safety and Tolerability of At-301 Nasal Spray Being Developed for Covid-19.
Atossa Therapeutics - At-301 Was Found to Be Safe and Well Tolerated in Study at Two Different Dose Levels.
Atossa Therapeutics - There We No Serious Adverse Events, No Discontinuations in Study.
Atossa Therapeutics - Co in Process of Preparing Pre-ind Meeting Request With U.S. FDA Which Co Plans to Submit in Next 30 Days.